Editorial & Advertiser disclosure

Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

AstraZeneca boosts CEO Soriot's pay to about $24 million for 2025

Published by Global Banking & Finance Review®

Posted on February 24, 2026

1 min read

Last updated: February 24, 2026

AstraZeneca boosts CEO Soriot's pay to about $24 million for 2025 - Finance news and analysis from Global Banking & Finance Review

Tags:Executive Compensation corporate governance

Quick Summary

AstraZeneca raised CEO Pascal Soriot’s 2025 pay 6.4% to £17.7m ($23.9m), driven by a £4.3m bonus up ~22% from 2024. The move keeps him among the FTSE 100’s top-paid chiefs as earnings improved.

AstraZeneca Raises CEO Pascal Soriot's 2025 Pay to Nearly $24 Million

FTSE 100 Context

Total Pay and Year-over-Year Change

Soriot's 2025 Compensation Breakdown

Feb 24 (Reuters) - AstraZeneca Chief Executive Pascal Soriot's 2025 pay rose 6.4% to 17.7 million pounds ($23.87 million) boosted by higher annual bonuses, keeping him among the FTSE 100's highest-paid executives, a filing showed on Tuesday.

Annual Bonus Increase

AstraZeneca, which is London's most valuable company and whose earnings jumped in 2025, paid Soriot 4.3 million pounds in annual bonus last year, up about 22% from 2024 levels, according to the company's annual report.

Exchange Rate Used

($1 = 0.7415 pounds)

Reporting and Editing Credits

(Reporting by Raechel Thankam Job in Bengaluru; Editing by Shailesh Kuber)

Key Takeaways

•Pascal Soriot’s total 2025 pay increases 6.4% to £17.7m ($23.9m).
•Annual bonus rises to £4.3m, about 22% higher than 2024.
•Soriot remains among the FTSE 100’s top-paid executives.
•AstraZeneca’s 2025 earnings improved, supporting the pay uptick.
•Company cites higher annual bonuses as the key driver of the increase.

Frequently Asked Questions about AstraZeneca boosts CEO Soriot's pay to about $24 million for 2025

1What is the main topic?

AstraZeneca increased CEO Pascal Soriot’s 2025 compensation to £17.7m ($23.9m), a 6.4% rise from the prior year. The boost was led by a larger annual bonus.

2How much did the annual bonus change?

Soriot’s annual bonus reached £4.3m for 2025, about 22% higher than in 2024, contributing significantly to the overall pay increase.

3Why is this relevant to investors?

The pay rise reflects AstraZeneca’s stronger 2025 performance and ongoing executive-compensation debates in the FTSE 100, which can influence governance and sentiment.

Soriot's 2025 Compensation Breakdown

Annual Bonus Increase

Exchange Rate Used

($1 = 0.7415 pounds)

Reporting and Editing Credits

(Reporting by Raechel Thankam Job in Bengaluru; Editing by Shailesh Kuber)

Key Takeaways

•Pascal Soriot’s total 2025 pay increases 6.4% to £17.7m ($23.9m).

•Annual bonus rises to £4.3m, about 22% higher than 2024.

•Soriot remains among the FTSE 100’s top-paid executives.

•AstraZeneca’s 2025 earnings improved, supporting the pay uptick.

•Company cites higher annual bonuses as the key driver of the increase.

Frequently Asked Questions

1What is the main topic?

AstraZeneca increased CEO Pascal Soriot’s 2025 compensation to £17.7m ($23.9m), a 6.4% rise from the prior year. The boost was led by a larger annual bonus.

2How much did the annual bonus change?

Soriot’s annual bonus reached £4.3m for 2025, about 22% higher than in 2024, contributing significantly to the overall pay increase.

3Why is this relevant to investors?

The pay rise reflects AstraZeneca’s stronger 2025 performance and ongoing executive-compensation debates in the FTSE 100, which can influence governance and sentiment.